Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where K. Zhao is active.

Publication


Featured researches published by K. Zhao.


International Journal of Radiation Oncology Biology Physics | 2010

THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IS ELECTIVE NODAL IRRADIATION NECESSARY?

K. Zhao; Jin-bo Ma; Guang Liu; Kai-Liang Wu; Xue-Hui Shi; Guo-Liang Jiang

PURPOSE To evaluate the local control, survival, and toxicity associated with three-dimensional conformal radiotherapy (3D-CRT) for squamous cell carcinoma (SCC) of the esophagus, to determine the appropriate target volumes, and to determine whether elective nodal irradiation is necessary in these patients. METHODS AND MATERIALS A prospective study of 3D-CRT was undertaken in patients with esophageal SCC without distant metastases. Patients received 68.4 Gy in 41 fractions over 44 days using late-course accelerated hyperfractionated 3D-CRT. Only the primary tumor and positive lymph nodes were irradiated. Isolated out-of-field regional nodal recurrence was defined as a recurrence in an initially uninvolved regional lymph node. RESULTS All 53 patients who made up the study population tolerated the irradiation well. No acute or late Grade 4 or 5 toxicity was observed. The median survival time was 30 months (95% confidence interval, 17.7-41.8). The overall survival rate at 1, 2, and 3 years was 77%, 56%, and 41%, respectively. The local control rate at 1, 2, and 3 years was 83%, 74%, and 62%, respectively. Thirty-nine of the 53 patients (74%) showed treatment failure. Seventeen of the 39 (44%) developed an in-field recurrence, 18 (46%) distant metastasis with or without regional failure, and 3 (8%) an isolated out-of-field nodal recurrence only. One patient died of disease in an unknown location. CONCLUSIONS In patients treated with 3D-CRT for esophageal SCC, the omission of elective nodal irradiation was not associated with a significant amount of failure in lymph node regions not included in the planning target volume. Local failure and distant metastases remained the predominant problems.


Diseases of The Esophagus | 2016

Reduced toxicity with three-dimensional conformal radiotherapy or intensity-modulated radiotherapy compared with conventional two-dimensional radiotherapy for esophageal squamous cell carcinoma: a secondary analysis of data from four prospective clinical trials.

Jiaying Deng; Chuanqing Wang; Xue-Hui Shi; G. Jiang; Wang Y; Liu Y; K. Zhao

We conducted a retrospective analysis to assess the toxicity and long-term survival of esophageal squamous cell carcinoma patients treated with three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) versus conventional two-dimensional radiotherapy (2DRT). All data in the present study were based on four prospective clinical trials conducted at our institution from 1996 to 2004 and included 308 esophageal squamous cell carcinoma patients treated with 2DRT or 3DCRT/IMRT. Based on the inclusion and exclusion criteria, 254 patients were included in the analysis. Of these patients, 158 were treated with 2DRT, whereas 96 were treated with 3DCRT/IMRT. The rates of ≥Grade3 acute toxicity of the esophagus and lung were 11.5% versus 28.5% (P = 0.002) and 5.2% versus 10.8% (P = 0.127) in the 3DCRT/IMRT and 2DRT groups, respectively. The incidences of ≥Grade 3 late toxicity of the esophagus and lungs were 3.1% versus 10.7% (P = 0.028) and 3.1% versus 5.7% (P = 0.127) in the 3DCRT/IMRT and 2DRT groups, respectively. The 1-year, 3-year and 5-year estimated overall survival rates were 81%, 38% and 34% in the 3DCRT/IMRT group and 79%, 44% and 31% in the 2DRT group, respectively (P = 0.628). The 1-year, 3-year and 5-year local control rates were 88%, 71% and 66% in the 3DCRT/IMRT group and 84%, 66% and 60% in the 2DRT group, respectively (P = 0.412). Fewer incidences of acute and late toxicities were observed in esophageal squamous cell carcinoma patients treated with 3DCRT/IMRT compared with those treated with 2DRT. No significant survival benefit was observed with the use of 3DCRT/IMRT.


International Journal of Radiation Oncology Biology Physics | 2005

Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: A phase III randomized study

K. Zhao; Xue-Hui Shi; Guo-Liang Jiang; Weiqiang Yao; Xiaomao Guo; Gen-di Wu; Long-Xiang Zhu


International Journal of Radiation Oncology Biology Physics | 2004

Late-course accelerated hyperfractionated radiotherapy for localized esophageal carcinoma

K. Zhao; Xue-Hui Shi; Guo-Liang Jiang; Yang Wang


Clinical Oncology | 2006

Association of Haemoglobin Level with Morbidity and Mortality of Patients with Locally Advanced Oesophageal Carcinoma Undergoing Radiotherapy — A Secondary Analysis of Three Consecutive Clinical Phase III Trials

K. Zhao; G. Liu; Guo-Liang Jiang; Yang Wang; L.-J. Zhong; Weiqiang Yao; Xiaomao Guo; Gen-di Wu; Long-Xiang Zhu; Xue-Hui Shi


World Journal of Gastroenterology | 2003

Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma

K. Zhao; Yang Wang; Xue-Hui Shi


International Journal of Radiation Oncology Biology Physics | 2013

Characteristics of Lymph Node Recurrence After Radical Surgery and Their Value in Target Volume Delineation in Postoperative Radiation Therapy for Thoracic Esophageal Squamous Cell Carcinoma

Qi Liu; Xu-Wei Cai; Bin Wu; Wen Yu; K. Zhao; X. Fu


International Journal of Radiation Oncology Biology Physics | 2014

Specific Lymphocytes Subsets Are Associated With Stage and Overall Survival of Esophageal Squamous Cell Carcinoma Patients Treated With Radiation Therapy

Yuhan Chen; Z. Zhang; G. Jiang; B. Ping; K. Zhao


International Journal of Radiation Oncology Biology Physics | 2014

Patient Features–Based Dosimetric Pareto Front Prediction in Esophagus Cancer Radiation Therapy

J. Wang; Xiance Jin; K. Zhao; Junjie Peng; J Xie; J. Cheng; W Hu


International Journal of Radiation Oncology Biology Physics | 2011

A Phase I Dose Escalation Study of Nimotuzumab in Combination with Concurrent Chemoradiotherapy for Patient with Locally Advanced Squamous Cell Cancer of Esophagus (ESO)

K. Zhao; G. Jiang; X. Hu; X. Wu; X. Fu; M. Fan

Collaboration


Dive into the K. Zhao's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge